- Home
- PINE vs SLS Comparison
PINE vs SLS Comparison
Compare PINE & SLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PINE | SLS |
|---|---|---|
| Founded | 2019 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 235.6M | 208.0M |
| IPO Year | 2019 | N/A |
Fundamental Metrics
Financial Performance| Metric | PINE | SLS |
|---|---|---|
| Price | $16.80 | $3.29 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | ★ $17.67 | $7.00 |
| AVG Volume (30 Days) | 200.2K | ★ 7.2M |
| Earning Date | 02-05-2026 | 11-12-2025 |
| Dividend Yield | ★ 6.88% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $57,423,000.00 | N/A |
| Revenue This Year | $14.13 | N/A |
| Revenue Next Year | $2.05 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 14.81 | N/A |
| 52 Week Low | $13.10 | $0.85 |
| 52 Week High | $17.88 | $3.44 |
Technical Indicators
Market Signals| Indicator | PINE | SLS |
|---|---|---|
| Relative Strength Index (RSI) | 53.56 | 85.04 |
| Support Level | $16.22 | $2.60 |
| Resistance Level | $16.52 | $2.31 |
| Average True Range (ATR) | 0.36 | 0.30 |
| MACD | -0.11 | 0.12 |
| Stochastic Oscillator | 34.34 | 68.14 |
Price Performance
Historical ComparisonAbout PINE Alpine Income Property Trust Inc.
Alpine Income Property Trust Inc is a real estate investment trust (REIT) that owns and operates a high-quality portfolio of commercial net lease properties in the United States. The company's portfolio predominantly comprises single-tenant retail properties located in or near metropolitan statistical areas, or MSAs. It operates in two business segments: income properties, which derive maximum revenue, and commercial loans and investments.
About SLS SELLAS Life Sciences Group Inc.
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.